Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp Alfa Monotherapy in Advanced Cervical Cancer
NCT04246489Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Mar 2020
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 12
01
Overview
A Phase 2 trial of bintrafusp alfa in Cervical Cancer (CC), sponsored by EMD Serono. Started Mar 2020; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04246489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246489.